Can Zytronic plc Beat AstraZeneca plc In 2016?

Zytronic plc (LON: ZYT) and AstraZeneca plc (LON: AZN) both have long-term growth potential

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Judging by yesterday’s full-year results release, Zytronic (LSE: ZYT) is trading well.

Compared to a year ago, revenue is up 13%, pre-tax profit up 39% and net cash from operations up around 17%. The directors marked this achievement by pumping up the dividend by 20% — nice!

On a roll

The British manufacturer makes interactive touch sensor products for things such as automatic transaction machines (ATMs), bill payment and financial information kiosks, vending machines and other commercial or industrial applications where humans interact with machines.

Although based and manufacturing from three modern factories in Blaydon upon Tyne in the UK, most of Zytronic’s production ships abroad — isn’t that wonderful! The firm works hard to improve its regional routes to market and established a technical support hub in the US in 2014. Now with eyes on the Greater China Region, Zytronic plans to set up what it calls a business- development and sales-opportunity-generation hub somewhere in Asia.

Such moves encourage me to believe that the firm has great potential for further growth from here.

The company’s recent financial record is good:

Year to September

2013

2014

2015

Revenue (£m)

17.28

18.89

21.27

Pre-tax profit (£m)

1.94

3.26

4.54

Net cash from operations (£m)

3.27

4.18

4.86

Rising revenue is generating a healthy percentage of profit and it is all backed up with solid cash flow from operations. During 2015, Zytronic further bolstered its already-strong balance sheet by adding £2 million to its cash reserves.

Valuation

Today’s 415p share price puts the firm on a forward price-to-earnings (P/E) multiple of just over 16 for 2016. The forward dividend yield comes in at 2.9%, and City analysts following the firm expect forward earnings to grow 3% that year and to cover the payout more than twice.

That valuation does look up with events, but the long-term potential for Zytronic is attractive. The firm deserves a place on my watch list, and any share-price weakness from here could be an opportunity to buy better value.

Building potential

Pitching Zytronic against AstraZeneca (LSE: AZN) makes it difficult to predict which of the two firms will do better for investors during 2016. AstraZeneca’s development pipeline is a potential powerhouse for new best-selling drugs and could hit the jackpot at any time. On top of that, the pharmaceutical giant operates an acquisition strategy that serves to reassure me that the firm remains serious about growth.

At today’s 4440p share price, AstraZeneca trades on a forward P/E rating of just under 17 for 2016 and there is a dividend yield of around 4.4% for investors to collect while waiting for any future growth spurt to kick in.

On balance, both Zytronic and AstraZeneca ooze with longer-term potential and maybe both would sit well in a portfolio with a five-year-plus investment horizon. That’s why I’m keeping an eye on both firms and may hit the ‘buy’ button on any temporary setback that knocks either firm’s share price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »